These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9685058)

  • 61. Biodynamic signatures from ex vivo bone marrow aspirates are associated with chemotherapy-induced neutropenia in cancer-bearing dogs.
    Marcum BA; Li Z; Turek JJ; Moore GE; Nolte DD; Childress MO
    Vet Med Sci; 2021 May; 7(3):665-673. PubMed ID: 33369129
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
    Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Féty R; de Bruijn E; Hempel G; Karlsson M; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH;
    Clin Pharmacokinet; 2007; 46(12):1051-68. PubMed ID: 18027989
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
    Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
    Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.
    Miya T; Goya T; Fujii H; Ohtsu T; Itoh K; Igarashi T; Minami H; Sasaki Y
    Invest New Drugs; 2001; 19(1):61-7. PubMed ID: 11291833
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.
    Danesi R; Conte PF; Del Tacca M
    Clin Pharmacokinet; 1999 Sep; 37(3):195-211. PubMed ID: 10511918
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy.
    Canal P; Gamelin E; Vassal G; Robert J
    Pathol Oncol Res; 1998; 4(3):171-8. PubMed ID: 9761935
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry.
    Dobbs NA; Twelves CJ; Gillies H; James CA; Harper PG; Rubens RD
    Cancer Chemother Pharmacol; 1995; 36(6):473-6. PubMed ID: 7554038
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
    Twelves CJ; Dobbs NA; Michael Y; Summers LA; Gregory W; Harper PG; Rubens RD; Richards MA
    Br J Cancer; 1992 Oct; 66(4):765-9. PubMed ID: 1419619
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Indocyanine green clearance in critically ill patients.
    Pollack DS; Sufian S; Matsumoto T
    Surg Gynecol Obstet; 1979 Dec; 149(6):852-4. PubMed ID: 388703
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
    Gabizon A; Isacson R; Rosengarten O; Tzemach D; Shmeeda H; Sapir R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):695-702. PubMed ID: 17549475
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests.
    Twelves CJ; Dobbs NA; Gillies HC; James CA; Rubens RD; Harper PG
    Cancer Chemother Pharmacol; 1998; 42(3):229-34. PubMed ID: 9685058
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.